^
    13d
    2022-BRL-501: Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Shanghai Changzheng Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> May 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    cyclophosphamide • fludarabine IV
    14d
    Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Shanghai Changzheng Hospital | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    2ms
    PERSIST: Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials (clinicaltrials.gov)
    P=N/A, N=178, Enrolling by invitation, AvenCell Therapeutics, Inc.
    New trial
    2ms
    Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC). (PubMed, Clin Cancer Res)
    Robust expansion of P-PSMA-101 CAR T cells resulted in toxicity but also durable responses in patients with mCRPC. Future trials of CAR T may be informed by the results with this nonviral engineering, TSCM cell-enriched approach.
    P1 data • Journal • IO biomarker
    |
    CASP9 (Caspase 9)
    5ms
    TmPSMA-02 in mCRPC (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Pennsylvania | Active, not recruiting --> Recruiting
    Enrollment open
    |
    TmPSMA-02
    8ms
    TmPSMA-02 in mCRPC (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | N=18 --> 8
    Enrollment closed • Enrollment change
    |
    TmPSMA-02
    10ms
    Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • engineered autologous T cells
    11ms
    Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging. (PubMed, Proc Natl Acad Sci U S A)
    Herein, we develop an approach for in situ T cell generation, tracking, and functional assessment using anti-CD5-conjugated lipid nanoparticles for codelivering CD19 CAR mRNA (mCAR19) and a prostate-specific membrane antigen mRNA (mPSMA) tag. With interleukin-7 (IL-7) preconditioning and repeated administration, this approach achieves tumor-free survival in 75% of B cell lymphoma-bearing mice (similar efficacy to ex vivo approaches), and through PET imaging of 68Ga-PSMA-617, the generation and tumor infiltration of in situ-engineered PSMA-tagged CD19 CAR-T cells is validated.
    Journal
    |
    IL7 (Interleukin 7)
    1year
    Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=3, Recruiting, Shanghai Changzheng Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    1year
    Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=3, Not yet recruiting, Shanghai Changzheng Hospital
    New P1 trial
    1year
    P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) (clinicaltrials.gov)
    P1, N=40, Terminated, Poseida Therapeutics, Inc. | N=60 --> 40 | Trial completion date: Sep 2036 --> Sep 2024 | Active, not recruiting --> Terminated; Study closed
    Enrollment change • Trial completion date • Trial termination
    |
    rimiducid (AP1903)
    over1year
    GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy. (PubMed, Mol Ther)
    In addition, PSMA-BB-Z-GITRL CAR-T cells produce higher levels of IFN-γ, TNF-α and IL-9 in mouse blood, exhibiting a higher proportion of TCM cells and a lower proportion of Treg cells compared to PSMA-BB-Z CAR-T cells. Our results demonstrate that the overexpression of GITRL has important implications for improving CAR-T cell-based human solid tumor immunotherapy.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)